---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-051532"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:56:19.175015+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics enters into $50M ATM equity offering with Leerink Partners

## Summary
- Xilio entered into Sales Agreement with Leerink Partners to sell up to $50M of common stock via ATM offering.
- Agent Leerink will receive 3.0% commission on gross proceeds from any shares sold under the agreement.
- Sales will be made on Nasdaq Global Select Market under effective S-3 registration statement filed Nov 2022.
- No minimum sales obligation; company retains discretion over timing and amount of any sales.
- The ATM facility was established on March 11, 2025; either party may terminate upon written notice.

## SEC filing metadata
- accession: 0001193125-25-051532
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312525051532/0001193125-25-051532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312525051532/d897420d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-051532
- JSON: https://secwatch.observer/filing/0001193125-25-051532.json
- Plain text: https://secwatch.observer/filing/0001193125-25-051532.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.